Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tbingen, Germany.

CureVac N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE MINIMUM CONDITION FOR THE OFFER HAS BEEN SATISFIED, WITH 184,071,410 SHARES OF CUREVAC, REPRESENTING APPROXIMATELY 81.74% OF CUREVAC'S ISSUED AND OUTSTANDING SHARES, TENDERED PRIOR TO THE EXPIRATION OF THE INITIAL OFFERING PERIOD THE SUBSEQUENT OFFERING PERIOD HAS COMMENCED AND WILL EXPIRE AT 12:01 A.M. EASTERN TIME ON THURSDAY, DECEMBER 18, 2025  MAINZ, GERMANY, DECEMBER 3, 2025  BIONTECH SE (NASDAQ: BNTX, BIONTECH) ANNOUNCED TODAY THAT 184,071,410 SHARES OF CUREVAC N.V.

BIONTECH ACHIEVES MINIMUM CONDITION IN CUREVAC EXCHANGE OFFER

TBINGEN, DE AND BOSTON, MA / ACCESS NEWSWIRE / NOVEMBER 25, 2025 / CUREVAC N.V. (NASDAQ:CVAC)(CUREVAC OR THE COMPANY), A PIONEERING MULTINATIONAL BIOTECH COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RNA (MRNA), TODAY ANNOUNCED THE VOTING RESULTS OF ITS EXTRAORDINARY GENERAL MEETING (EGM).

CUREVAC ANNOUNCES VOTING RESULTS OF EXTRAORDINARY GENERAL MEETING

GERMAN FEDERAL CARTEL OFFICE CLEARANCE OBTAINED FOR THE PLANNED BIONTECH - CUREVAC TRANSACTION ANNOUNCED ON JUNE 12, 2025, MARKING AN IMPORTANT STEP TOWARD THE EXPECTED CLOSING LATER THIS YEAR OFFER PERIOD FOR BIONTECH'S PUBLIC EXCHANGE OFFER FOR ALL OUTSTANDING CUREVAC N.V. SHARES BEGAN ON OCTOBER 21, 2025, AND IS SCHEDULED TO EXPIRE ON DECEMBER 3, 2025 GERMAN LITIGATION WITH PFIZER/BIONTECH RELATED TO MRNA-BASED COVID-19 VACCINES HAS BEEN PAUSED PENDING COMPLETION OF BIONTECH'S PUBLIC EXCHANGE OFFER RECEIVED CLINICAL TRIAL APPLICATION (CTA) CLEARANCE FROM THE EUROPEAN MEDICINES AGENCY (EMA) FOR CVHNLC SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC) CVGBM (GLIOBLASTOMA) PHASE 1 PART B REMAINS ON TRACK STRONG CASH AND CASH EQUIVALENTS POSITION OF 416.1 MILLION AS OF SEPTEMBER 30, 2025, CONFIRMING EXPECTED CASH RUNWAY INTO 2028 CUREVAC RECEIVED FINAL AUDIT REPORT RELATING TO THE ADVANCE PURCHASE AGREEMENT WITH THE EUROPEAN COMMISSION FOR CUREVAC'S FIRST-GENERATION COVID-19 VACCINE CANDIDATE TBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / NOVEMBER 24, 2025 / CUREVAC N.V.

CureVac N.V.

CVAC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CureVac N.V.

CVAC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CVAC